Wegovy, Ozempic drive Novo Nordisk to $500 billion valuation | Fortune Europe

The drugmaker saw a 150% increase in sales for its GLP-1s, now it thinks the worst of a supply chain glut may be over.

Do you trust this headline?

Based on recent headline ratings, 77% of this readership currently trusts the local media, which has an average score of 89% regionally and is currently trending negative.

77%

Media Trust Score77%